Clinical Trial

Pathogenesis of Periodontal Disease in Individuals With Psoriasis

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 5, 2025 (before its estimated February 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to evaluate the levels of Th17 cell-associated cytokines (IL-17, IL-21, IL-23) and the salivary stress biomarkers cortisol, dehydroepiandrosterone, and Chromogranin A in the pathogenesis of periodontal disease in individuals with psoriasis, thereby revealing immunological and neuroendocrine interactions. The fundamental question it aims to answer is: What are the biological mechanisms that may increase the risk of periodontal disease in individuals with psoriasis? In this context, the periodontal status of individuals with psoriasis will be clinically assessed, followed by analysis of the levels of Th17-associated cytokines and stress biomarkers in gingival crevicular fluid and saliva samples. Additionally, patients will be asked questions from the Social Appearance Anxiety Scale. The periodontal status of individuals with psoriasis will be determined cross-sectionally, and the resulting biomarker levels will be examined. In addition, the data obtained will be evaluated with statistical analysis in relation to disease severity and clinical parameters.
Trial Details
NCT Number NCT07158125
Lead Sponsor Recep Tayyip Erdogan University Training and Research Hospital
Conditions Psoriasis
Enrollment 60 participants
Start Date 2025-09-15
Primary Completion 2026-02-02 (estimated)
Study Completion 2026-04-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-05